Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 7,719 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Recruiting Not applicable Interventional

Effect of Neuro20 Functional Electrical Stimulation Suit on Autonomic Function, Muscle Performance, and Gait

NCT07164846
View directory record Official record
Conditions
Spinal Cord Injury, Stroke, Amputees
Interventions
Therapy Sessions
Device
Lead sponsor
Brooks Rehabilitation
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Exercise Neuroprotection in Parkinson's Disease

NCT05854524
View directory record Official record
Conditions
Parkinson Disease
Interventions
Aerobic exercise
Procedure
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
30 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

NCT01222780
View directory record Official record
Conditions
Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia, Lymphoma, Brain Tumors
Interventions
Marqibo
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years to 20 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Not applicable Interventional

Social Incentives to Increase Mobility

NCT03321279
View directory record Official record
Conditions
Pneumonia, Diabetes, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
Social Incentive
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

NCT03875079
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
RO6874281, Pembrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
New Haven, Connecticut • Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Not applicable Interventional

Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors

NCT00066482
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Interventions
bleomycin sulfate, filgrastim, cisplatin, cyclophosphamide, etoposide, conventional surgery, MESNA
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

NCT00003451
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant interferon alfa, recombinant interleukin-12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 21, 2026, 10:30 PM EDT
Available No phase listed Expanded access

Expanded Access to Gallium Maltolate (GaM)

NCT06404034
View directory record Official record
Conditions
Glioblastoma, Refractory Glioblastoma, Glioblastoma Multiforme
Interventions
Gallium Maltolate
Drug
Lead sponsor
Imaging Biometrics, LLC
Industry
Eligibility
18 Years and older
U.S. locations
3
States / cities
Miami, Florida • Lincoln, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Recruiting Phase 1 Interventional

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

NCT07509034
View directory record Official record
Conditions
Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Refractory Small Cell Lung Cancer, Extrapulmonary Small Cell Carcinoma, Neuroendocrine Carcinoma, Poorly Differentiated Neuroendocrine Carcinoma, High-Grade Neuroendocrine Carcinoma
Interventions
Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

NCT01059864
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Atorvastatin, Atorvastatin Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

NCT03267732
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Pegilodecakin
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Not yet recruiting Phase 1 Interventional

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

NCT07617363
View directory record Official record
Conditions
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Interventions
ATRN-119, Decitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Terminated Not applicable Interventional

Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM)

NCT04269655
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Cloud-Based Continuous Glucose Monitoring
Device
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 21, 2026, 10:30 PM EDT
Completed No phase listed Observational

Sensory Processing in Tourette Syndrome

NCT02512406
View directory record Official record
Conditions
Tourette Syndrome
Interventions
The Sensory Profile, The Adult/Adolescent Sensory Profile, Children's Yale-Brown Obsessive Compulsive Scale, Yale-Brown Obsessive Compulsive Scale, Yale Global Tic Severity Scale, Demographic Data
Other
Lead sponsor
University of Florida
Other
Eligibility
6 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Increase Psychological Well-being by the Implementation of Forgiveness Education

NCT04403126
View directory record Official record
Conditions
Anger, Depressive Symptoms, Anxiety
Interventions
forgiveness education intervention
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
10 Years to 65 Years
Enrollment
1,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 21, 2026, 10:30 PM EDT
Active, not recruiting Not applicable Interventional

ResIlience-based Stigma REdUction Program ("Rise-up")

NCT05174936
View directory record Official record
Conditions
HIV/AIDS, Stigma, Social, Emotional Adjustment
Interventions
PLWH intervention, Family member intervention, Healthcare provider intervention
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1,928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care

NCT03465371
View directory record Official record
Conditions
Psychosis
Interventions
CSC OnDemand Training Intervention, InPerson Intervention, Virtual InPerson Intervention
Other
Lead sponsor
Center for Social Innovation, Massachusetts
Other
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

NCT00469209
View directory record Official record
Conditions
Myeloma
Interventions
Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Not applicable Interventional Results available

Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life)

NCT06706999
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Arthritis, Rheumatoid (RA)
Interventions
PREVAIL model of care
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Not applicable Interventional Results available

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

NCT00984399
View directory record Official record
Conditions
Atrophic Vaginitis, Breast Cancer
Interventions
Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 21, 2026, 10:30 PM EDT
Terminated Not applicable Interventional Results available

Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)

NCT01881932
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer
Interventions
Acupuncture using Seirin® needles, Sham Acupuncture using Park Sham placebo acupuncture device
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acute Headache Treatment in Pregnancy: Occipital Nerve Block vs PO Acetaminophen With Caffeine

NCT03951649
View directory record Official record
Conditions
Headache, Pregnancy Related, Occipital Nerve Block
Interventions
Occipital Nerve Block
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 60 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 21, 2026, 10:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

NCT07061938
View directory record Official record
Conditions
IgG4 Related Disease
Interventions
ACE1831, Lymphodepleting chemotherapy
Drug
Lead sponsor
Acepodia Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Terminated Phase 3 Interventional

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

NCT00009906
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
Imatinib Mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
132
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 99 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 21, 2026, 10:30 PM EDT